SecBot SecBot
SECBOTREPLAY Home › Report › EVAX

EVAX · Evaxion announced new preclinical data for its off-the-shelf AML…

Evaxion · PRESS-RELEASE filed Jun 11, 2026 at 02:00 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Jun 11, 2026 at 02:00 ET

Evaxion announced new preclinical data for its off-the-shelf AML vaccine EVX-04, demonstrating complete expression in human cells, immune recognition/activation, and targeted cell-killing across diverse human immune profiles. The data will be presented at EHA 2026 Congress on June 13, 2026, and the company is preparing a regulatory filing for clinical testing. This is positive but early-stage, with no revenue or timeline to clinic.

  • EVX-04 is an off-the-shelf therapeutic vaccine for acute myeloid leukemia developed using the AI-Immunology™ platform.
  • Preclinical data shows EVX-04 is successfully expressed, secreted in human cells, and induces specific immune responses and targeted cell-killing.
  • Data will be presented at the EHA 2026 Congress in Stockholm, Sweden on June 13, 2026.
  • The company is preparing a regulatory filing to begin clinical testing, but no timeline for an IND/CTA or first-in-human study was provided.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access